ArticleJournal of inflammation research2025
Rhoifolin Attenuates DSS-Induced Colitis in Mice by Modulating Gut Microbiota and Restoring Th17/Treg Balance.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Carrier-free supramolecular architectonics of quercetinMaterials today. Bio · 2026Article
- Pharmacology-Driven Dissection of Core Component Sets of Xuefu Zhuyu Decoction in Blood Stasis-Related Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rhoifolin (ROF), a flavonoid compound isolated from citrus plants, has been shown in modern research to possess a range of important biological activities, including anti-inflammatory and anti-tumor properties. Methods: In this study, we induced ulcerative colitis (UC) in mice using dextran sulfate sodium (DSS) and treated them with ROF during the therapeutic phase. Results: The results showed that ROF significantly alleviated the weight loss, colon shortening, and histopathological damage in the colon tissues of the mice, while also improving intestinal barrier function by restoring the expression of ZO-1 and E-cadherin. 16S rDNA sequencing analysis indicated that ROF treatment significantly altered the diversity and composition of the gut microbiota, increasing the relative abundance of Discussion: In conclusion, we provides the first evidence that ROF alleviates DSS-induced colonic inflammation by modulating gut microbiota diversity, restoring the Th17/Treg cell balance, and inhibiting the IL-17 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.